GI-Safer Formulation of Indomethacin for use in Preterm Neonates
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
批准号:
8313502
负责人:
Upendra Marathi
金额:
$56.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-05 至 2014-03-31
关键词:
ASBT proteinAccountingAdverse effectsAffectAgeAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryApplications GrantsAttenuatedBile AcidsBile fluidBirth WeightBlood CirculationBreast FeedingBronchopulmonary DysplasiaCardiovascular systemCessation of lifeChronicConsultationsConsumptionContractsDevelopmentDietDigestive System DisordersDiseaseDrug FormulationsDrug toxicityEmergency SituationEtiologyEvaluationGastrointestinal DiseasesGastrointestinal InjuryGastrointestinal tract structureGlucocorticoidsGoalsGrantHealth SciencesHemorrhageHospitalsHumanIndomethacinInflammationInjuryInstitutionIntestinal PerforationIntestinesIntravenousKnockout MiceLeadLecithinLegal patentLifeLow Birth Weight InfantLower Gastrointestinal TractLungManufacturer NameMedicineModelingMorbidity - disease rateMucous MembraneMusNecrotizing EnterocolitisNeonatalNeonatal Intensive Care UnitsObstructionOperative Surgical ProceduresPatent Ductus ArteriosusPathogenesisPathway interactionsPerforationPharmaceutical PreparationsPhasePhase I Clinical TrialsPlayPregnancyPremature InfantProductionPropertyRattusResearch PersonnelResistanceRiskRisk FactorsRodentRoleSafetySepsisSmall Business Innovation Research GrantSurfaceTechnology TransferTestingTexasTissuesToxic effectUniversitiesVery Low Birth Weight InfantWeaningbile acid transportercollegecommensal microbescommercializationcomparative efficacycongenital heart disorderfeedingforestgastrointestinalhigh riskimprovedintraventricular hemorrhagelung developmentmature animalmedical schoolsmortalityneonatenovelpathogenic bacteriapostnatalprematurepreventprototyperesearch studyscale upstandard carestandard of caresurfactanttherapy developmentuptake
中文摘要
描述(由申请人提供):本申请是SBIR第二期拨款。低出生体重新生儿发病和死亡的主要原因之一与下消化道损伤、炎症、穿孔和梗阻有关,可表现为相关疾病坏死性小肠结肠炎(NEC)和自发性肠穿孔(SIP)。这些消化系统疾病影响2-5%的早产儿,通常需要进行大手术,死亡率为20-50%。NEC和SIP的病因尚未完全阐明,已确定的危险因素除了出生体重<1.5 kg外,还包括配方喂养和使用吲哚美辛,这是治疗和/或预防动脉导管未闭(PDA)发展的标准护理方法,这种情况会导致肺血管循环短路,导致氧合不足,增加脑室内出血的风险。支气管肺发育不良和死亡在这个II期申请中,我们将进一步开发和评估一种新的专有肠外注射吲哚美辛配方,其中非甾体抗炎药与磷脂酰胆碱(PC)非共价结合,使其对胃肠道更安全。这种吲哚美辛- pc (PL4500)的组合物似乎可以减轻成年动物单独使用吲哚美辛引起的胃肠道损伤。在之前的一期实验中,我们发现断奶前母乳喂养的新生大鼠对吲哚美辛的胃肠道毒性有明显的抗性,而配方奶喂养的大鼠则没有。此外,在断奶期间,肠道胆汁酸和回肠胆汁酸摄取转运蛋白(顶钠依赖性胆汁酸转运蛋白,ASBT)的水平都在发育过程中增加,这可能与吲哚美辛的胃肠道毒性有关。了解吲哚美辛对胃肠道损伤的可能机制以及吲哚美辛- pc如何提供保护对以后的FDA备案非常重要。因此,第一个目的是通过比较不同出生年龄的母乳喂养和配方喂养小鼠的毒性,评估吲哚美辛- pc与未修饰的吲哚美辛对新生小鼠的胃肠道毒性;比较NEC模型的毒性;并比较野生型和ASBT敲除小鼠以及早期诱导表达ASBT小鼠的毒性。第二个目的是确定吲哚美辛- pc与吲哚美辛在PDA模型中的疗效。第三个目标是将技术转让给合同商业制造商,并开始扩大吲哚美辛pc的生产规模,目标是生产出一种适合稳定性、分散性和随后在I期临床试验中进行安全性评估的肠外制剂原型。该拨款提案中包含的开发活动将显著推动PL4500走向商业化。如果吲哚美辛- pc配方继续具有改善的胃肠道安全性,并且与吲哚美辛相比具有相同的疗效,它将通过降低发生NEC和SIP(胃肠道毁灭性疾病)的风险,代表着治疗潜在或确诊PDA的低出生体重新生儿的护理标准的重要改进。
英文摘要
DESCRIPTION (provided by applicant): This application is for a SBIR Phase II grant. One of the major causes of morbidity and mortality of low birth weight neonates relates to injury, inflammation, perforation and obstruction of the lower GI tract, which can be manifest in the related diseases Necrotizing Enterocolitis (NEC) and Spontaneous Intestinal Perforation (SIP). These digestive diseases, which affect 2-5% of preterm babies, frequently require major surgery and are associated with a mortality rate of 20-50%. The etiology of both NEC and SIP have yet to be fully elucidated, and risk factors that have been identified, in addition to a birth weight o <1.5 kg, include formula feeding and the use of indomethacin, the standard of care to treat and/or prevent the development of Patent Ductus Arteriosus (PDA), a condition which results in the circulation short-circuiting the pulmonary vasculature, leading to inadequate oxygenation, increasing the risk of intraventricular hemorrhage, bronchopulmonary dysplasia, and death. In this Phase II application we will further develop and evaluate a novel proprietary parenteral formulation of indomethacin, in which the NSAID is non-covalently associated with phosphatidylcholine (PC) to make it safer for the GI tract. This composition of Indomethacin-PC (PL4500) appears to reduce the GI injury caused by indomethacin alone in adult animals. In the prior Phase I experiments, we found that there was an apparent resistance to GI toxicity of indomethacin in rat neonates before weaning if the animals were breast- fed, but not if they were formula-fed. Also, during weaning there were developmentally increasing levels of both intestinal bile acid and ileal bile acid uptake transporter (apical sodium-dependent bile acid transporter, ASBT) which may be associated with indomethacin GI toxicity. It is important for later FDA filings to understand the possible mechanism of GI injury by indomethacin and how indomethacin-PC may offer protection. Thus, the first aim is to evaluate the GI toxicity of indomethacin-PC versus unmodified indomethacin in neonatal mice by comparing toxicity in breast-fed and formula-fed mice at different postnatal ages; comparing toxicity in a model of NEC; and comparing toxicity in wildtype and ASBT knockout mice and in mice induced to express ASBT early. The second aim is to determine the efficacy of indomethacin-PC versus indomethacin in a model of PDA. The third aim is to carry out technology transfer to a contract commercial manufacturer and initiate scale- up of Indomethacin-PC production, with the goal of yielding a prototype parenteral formulation that is suitable for stability, dispersibility, and subsequent safety evaluation in Phase I clinical trials. The development activities encompassed in this grant proposal will significantly advance PL4500 toward commercialization. If the Indomethacin-PC formulation continues to possess an improved GI safety profile, together with equivalent efficacy compared with indomethacin, it will represent an important improvement in the standard of care for the treatment of low birth weight neonates with potential or confirmed PDA, by reducing risk of developing NEC and SIP, devastating diseases of the GI tract.
PUBLIC HEALTH RELEVANCE: Low birth weight infants, that are born prematurely, are highly susceptible to a number of potentially life- threatening conditions including Patent Ductus Arteriosus (PDA) and Necrotizing Enterocolitis (NEC). PDA is a congenital disease of the heart commonly found in premature infants that can lead to inadequate oxygenation and death. The standard treatment for PDA is intravenous indomethacin (Indocin(R)) which is known to be associated with gastrointestinal (GI) tract side effects including: intestinal bleeding, perforatios and sepsis in mature animals and humans. NEC is the most common surgical emergency that affects premature infants in the neonatal intensive care unit causing perforations, excessive GI bleeding, and an invasion of pathogenic and commensal bacteria. It is our hypothesis that the use of Indocin(R) in low birth weight infants to treat PDA may be an important etiological factor in NEC. The product under development in this proposal, designated PL4500, is a formulation of indomethacin that is associated with phosphatidylcholine to make it safer for the GI tract, and help protect low birth weight babies from developing NEC-like disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A small molecule integrin activator to enhance cord blood transplant
-
批准号:9139272
-
项目类别:
-
资助金额:$29.59万
-
财政年份:2016
-
负责人:Upendra Marathi
-
依托单位:
A small molecule integrin activator to enhance cord blood transplant
-
批准号:9907800
-
项目类别:
-
资助金额:$93.6万
-
财政年份:2016
-
负责人:Upendra Marathi
-
依托单位:
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
-
批准号:9138564
-
项目类别:
-
资助金额:$31.37万
-
财政年份:2016
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
-
批准号:7910222
-
项目类别:
-
资助金额:$15.79万
-
财政年份:2010
-
负责人:Upendra Marathi
-
依托单位:
Clinical Evaluation of GI Safer Naproxen for the Treatment of Osteoarthritis
-
批准号:7925188
-
项目类别:
-
资助金额:$79.86万
-
财政年份:2010
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Formulation of Indomethacin for use in Preterm Neonates
-
批准号:8434115
-
项目类别:
-
资助金额:$55.29万
-
财政年份:2010
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related
-
批准号:7657930
-
项目类别:
-
资助金额:$74.57万
-
财政年份:2009
-
负责人:Upendra Marathi
-
依托单位:
GI-Safer Naproxen Formulation R&D for the Treatment of Osteoarthritis and Related
-
批准号:7537759
-
项目类别:
-
资助金额:$26.36万
-
财政年份:2008
-
负责人:Upendra Marathi
-
依托单位:
海外基金